Genetic Testing for Patients with a Maternal History of Ovarian Cancer

Clear Indication for Genetic Counseling Referral

The American College of Medical Genetics and Genomics, National Society of Genetic Counselors, and multiple international guidelines uniformly recommend that individuals with a first-degree relative with ovarian, fallopian tube, or primary peritoneal cancer should be referred for genetic counseling and offered genetic testing 1, 2
Having a mother with ovarian cancer represents one of the strongest family history criteria, requiring no additional affected relatives or age restrictions 1, 2, 3
This criterion applies regardless of the patient's current age or personal cancer history 2
The USPSTF specifically includes women who have family members with ovarian, tubal, or peritoneal cancer in their recommendation for genetic counseling 2, 4

Risk-reducing salpingo-oophorectomy (RRSO) performed between ages 35-40 for BRCA1 carriers and 40-45 for BRCA2 carriers dramatically reduces ovarian cancer mortality 5
BRCA mutation carriers also require enhanced breast cancer surveillance with MRI and mammography starting at age 25-30, which improves early detection and survival 5

Initial testing should be performed on the affected family member (the mother with ovarian cancer) who has the highest likelihood of carrying a mutation 3
If the mother tests positive for a specific mutation, the patient can then undergo targeted testing for that familial mutation, which is faster and less expensive 3, 5

Counseling should cover the probability of finding a mutation, implications for the patient and family members, and meaning of possible results including variants of uncertain significance 1, 2
Discussion must address how results will influence medical management, including enhanced surveillance and risk-reducing surgeries 2, 4
The European Society for Medical Oncology emphasizes that informed consent and genetic counseling must be completed before any BRCA testing 1

Enhanced breast surveillance with annual MRI and mammography beginning at age 25-30 5
Risk-reducing salpingo-oophorectomy recommended between ages 35-40 for BRCA1 carriers (after childbearing complete) 5
Risk-reducing salpingo-oophorectomy recommended between ages 40-45 for BRCA2 carriers 5
Cascade testing should be offered to other at-risk family members 1

The USPSTF gives a Grade D recommendation against ovarian cancer screening in all women, including those with family history, as it does not reduce mortality and causes significant harm through false-positive results 5, 6
Approximately 10% of screened women receive false-positive results, leading to unnecessary surgeries with a 20:1 ratio of surgeries to screen-detected cancers 6
Risk-reducing surgery, not screening, is the evidence-based approach for BRCA mutation carriers 5